SHANGHAI, May 7 (Reuters) - Start-up Chinese drug maker Zensun (Shanghai) Sci & Tech Co is aiming for a public listing in Nasdaq or London in 2011, its president and CEO said on Thursday.

The privately-held company has recently developed its first product, Neuregulin, which could help improve heart function, Mingdong Zhou told Reuters in an interview.

Zhou said he would hopefully apply for regulatory approval to sell Neuregulin in China at the end of 2010 or 2011 upon the completion of a final round of clinical tests.

"We will kick off the IPO process once we get approval to sell the drug in China," he said.

Zhou, also the chief executive of the firm, said that he is in talks with several U.S. pharmaceutical firms to sell the patent of Neuregulin and hopefully to gain the Food and Drug Administration's approval to sell it in the United States.

He did not name any firms. (Reporting by David Lin and Jacqueline Wong)